Financial Performance - The company's operating revenue for 2024 reached ¥33,351,653,828.95, representing a 4.05% increase compared to ¥32,052,121,586.44 in 2023[20]. - The net profit attributable to shareholders for 2024 was ¥525,522,107.14, a 7.53% increase from ¥488,732,096.82 in 2023[20]. - The net profit after deducting non-recurring gains and losses was ¥509,880,346.81, which is a 25.74% increase from ¥405,498,097.75 in 2023[20]. - The total assets at the end of 2024 amounted to ¥14,632,477,002.42, reflecting a 5.20% increase from ¥13,908,856,860.12 at the end of 2023[20]. - The company's basic earnings per share for 2024 was ¥1.02, down 6.42% from ¥1.09 in 2023[20]. - The company reported a cash flow from operating activities net amount of ¥410,324,781.82, a decrease of 3.52% compared to ¥425,313,727.37 in 2023[20]. - The company achieved a gross margin of 6.63% in pharmaceutical sales, with a slight increase of 0.25% year-on-year[65]. - The total operating revenue for 2024 reached ¥33.35 billion, representing a 4.05% increase from ¥32.05 billion in 2023[64]. - The pharmaceutical wholesale sector accounted for ¥29.93 billion, or 89.75% of total revenue, with a year-on-year growth of 2.90%[65]. - The pharmaceutical retail sector saw a significant increase of 15.46%, generating ¥3.18 billion, which is 9.53% of total revenue[64]. Dividends and Shareholder Engagement - The company plans to distribute a total cash dividend of 200 million CNY to all shareholders, with no stock dividends issued[4]. - The company implemented a stable cash dividend policy, with a cash dividend of 200 million yuan (including tax), representing 38.06% of the net profit attributable to shareholders[165]. - The cash dividend per 10 shares is set at 3.83 yuan (including tax), based on a total share capital of 521,892,509 shares[165]. - The total cash dividend amount, including other methods, is 200 million yuan, which accounts for 100% of the total profit distribution[165]. - The company ensures that minority shareholders have sufficient opportunities to express their opinions and that their legal rights are fully protected[164]. - The participation ratio for the 2024 first extraordinary shareholders' meeting was 73.16%[130]. - The participation ratio for the 2023 annual shareholders' meeting was 73.14%[130]. - The participation ratio for the 2024 second extraordinary shareholders' meeting was 73.26%[130]. Corporate Governance and Management - The financial report is guaranteed to be true, accurate, and complete by the company's board and management[4]. - The company has a strong leadership team with members having backgrounds in finance, law, and strategic management, enhancing its operational capabilities[137]. - The company emphasizes compliance and legal oversight, with dedicated roles for legal and risk management within its executive team[141]. - The company has appointed independent directors with significant academic and industry experience, contributing to its governance and strategic direction[139]. - The board of directors held a total of 13 meetings during the reporting period, with all resolutions reported to the Shenzhen Stock Exchange[147]. - The independent directors provided valuable professional advice on internal control, management system construction, and major decision-making[152]. - The company has established a robust incentive mechanism for senior management, aligning their performance with company goals[169]. - The management team is evaluated based on performance metrics directly linked to their compensation, promoting accountability and performance improvement[169]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements related to development strategies and future plans[4]. - The company is committed to maintaining high standards in quality and compliance, as indicated by the roles of its quality management team[135]. - The company adheres to strict quality management protocols to mitigate risks associated with product quality issues, which could lead to financial and reputational damage[119]. - The company is focused on enhancing its governance structure and talent acquisition strategies to optimize its workforce and improve operational efficiency[114]. - The company is committed to fulfilling all promises made during the acquisition process, with accountability for any breaches[185]. - The company will ensure compliance with relevant laws and regulations regarding related transaction decision-making procedures and information disclosure obligations[187]. Strategic Development and Market Position - The company is positioned in the pharmaceutical distribution industry, which is undergoing modernization and digital transformation, driven by increasing consumer demand and regulatory reforms[29]. - The company aims to enhance its market share in pharmaceuticals and expand its professional marketing efforts, targeting a leading position in every market segment within the province[111]. - The company plans to accelerate mergers and acquisitions, focusing on top-ranked pharmaceutical wholesale enterprises with a scale of over several billion in economically developed regions[115]. - The company is advancing its digital transformation, aiming to fully utilize data in its operations and enhance organizational efficiency[60]. - The company is focusing on high-value-added areas and exploring partnerships with commercial insurance to broaden payment channels and enhance customer service[118]. Community Engagement and Social Responsibility - The company is committed to social responsibility and sustainable development, aiming to create value for shareholders while contributing positively to society[111]. - The company donated 300,000 yuan to support sustainable development in rural areas, contributing to poverty alleviation efforts[181]. - The company has actively engaged in over 30 volunteer activities, involving 563 participants, to promote social responsibility and community support[180]. - The company is involved in strategic partnerships to enhance its service offerings and community impact[182]. Investments and Acquisitions - The company acquired 51% of Shenzhou Yintianhua Pharmacy and 100% of Hangzhou Guangji Huanlong Trading Co., expanding its market presence[70]. - The company has established a comprehensive provincial distribution network with six logistics centers and over 200 retail stores across 11 cities in Zhejiang province[40][42]. - The company initiated the construction of the Zhejiang Yinte Shitang Pharmaceutical Industrial Park, covering an area of 119 acres, to enhance logistics and industry incubation[59]. - The company is developing an end-to-end cold chain logistics system for vaccines, aiming for real-time monitoring and precise regulation[74]. Digital Transformation and Technology - The company is advancing its digital transformation to improve logistics efficiency and service quality through a comprehensive information management system[49]. - The government is promoting digital transformation in the pharmaceutical industry, emphasizing the integration of AI and big data technologies[34]. - The company has developed a digital energy monitoring platform to automate energy consumption data collection and analysis, enhancing operational efficiency[177]. Employee Management and Development - The total number of employees at the end of the reporting period is 3,072, with 1,695 in sales and 165 in finance[158]. - The company has established a training plan to enhance the skills of its workforce, focusing on high-quality talent development[161]. - The company has implemented a salary policy that links compensation to performance and strategic business support[160]. Financial Management and Internal Controls - The company has implemented an effective internal control system, ensuring compliance with laws and regulations, and enhancing operational efficiency[170]. - The internal control measures have met the expected objectives, safeguarding the interests of the company and its shareholders[170]. - The company maintained effective internal control over financial reporting as of December 31, 2024, according to the internal control audit report[174].

| 证券代码：000411 | 证券简称：英特集团 | 公告编号：2025-012 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 浙江英特集团股份有限公司 2025 年第一季度可转换公司债券转股情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 英特转债（债券代码：127028）转股期为 2021 年 7 月 12 日至 2027 年 1 月 4 日，截 至目前，转股价格为人民币 9.68 元/股。 根据《深圳证券交易所股票上市规则》《深圳证券交易所可转换公司债券业务实施细则》 的有关规定，浙江英特集团股份有限公司（以下简称"英特集团"或"公司"）现将 2025 年第 一季度可转换公司债券（以下简称"可转债"）转股及公司股份变动情况公告如下： 一、可转债发行上市基本情况 2022 年 9 月 21 日，公司召开九届二十次董事会议、九届十三次监事会议，审议通过了 《关于调整 2021 年限制性股票激励计划预留授予数量的议案》《关于向激励对象授予预留 部分限制性股票的议案》，鉴于公司已完成 ...

因公司本次回购注销部分限制性股票占公司总股本比例较小，经计算，"英特转债"的 转股价格不做调整。目前"英特转债"的转股价格为 9.68 元/股。 | 证券代码：000411 | 证券简称：英特集团 | 公告编号：2025-011 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 浙江英特集团股份有限公司 关于回购注销部分限制性股票不调整"英特转债"转股价 格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 一、关于可转换公司债券转股价格调整的相关规定 经中国证券监督管理委员会《关于核准浙江英特集团股份有限公司公开发行可转换公司 债券的批复》（证监许可[2020]3159 号）核准，同意浙江英特集团股份有限公司（以下简称 "公司"）向社会公开发行面值总额 6 亿元可转换公司债券，期限 6 年。经深圳证券交易所 同意，公司可转换公司债券自 2021 年 3 月 10 日起在深交所上市交易，债券简称为"英特转 债"，债券代码为"127028"。 根据《浙江英特集团股份有限公司公开发行可转换公司债 ...

| 证券代码：000411 | 证券简称：英特集团 公告编号：2025-010 | | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | 浙江英特集团股份有限公司 关于 2021 年限制性股票激励计划 部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： 1、浙江英特集团股份有限公司（以下简称"公司"）2021 年限制性股票激励计划 （以下简称"本激励计划"）本次回购注销的限制性股票数量为 259,440 股，占回购注 销前公司总股本的 0.05%。本次回购注销涉及首次授予 12 名激励对象，回购价格为 4.47 元/股，预留授予 3 名激励对象，回购价格为 4.87 元/股。本次回购注销完成后， 公司股份总数由 522,151,743 股减少至 521,892,303 股。 2、截至 2025 年 3 月 10 日，上述限制性股票已在中国证券登记结算有限责任公 司深圳分公司办理完成注销手续。 3、因本次回购注销股份占公司总股本比例较小，经计算，"英特转债"的转股价 格不作调整，转股价格 ...

Core Viewpoint - The recent leadership changes at Yingte Group, including the resignation of Chairman Ying Xueqi and the election of Wang Yang as the new chairman, are part of normal personnel adjustments within the company [1][3]. Company Overview - Yingte Group is a large regional pharmaceutical distribution enterprise in China, involved in various sectors including pharmaceuticals, medical devices, new retail, logistics, and traditional Chinese medicine, with a significant sales network in East China, particularly Zhejiang [2]. - The company is controlled by Zhejiang Provincial State-owned Assets Supervision and Administration Commission and has undergone several ownership changes since its establishment in 1950 [2][3]. Leadership Changes - Ying Xueqi has resigned from all positions within Yingte Group, while Wang Yang has been elected as the new chairman, with his term lasting until the current board's term ends [1][3]. - Ying Xueqi has a long tenure with the company, having joined in 1995, while Wang Yang has held various leadership roles within the organization [3][4]. Financial Performance - Yingte Group's revenue has grown significantly, surpassing 300 billion yuan, with annual revenues from 2018 to 2023 reported as follows: 204.92 billion, 246.01 billion, 250.08 billion, 267.31 billion, 306.19 billion, and 320.52 billion yuan [5]. - The company's profitability remains relatively weak, with gross and net profit margins consistently around 6%-6.8% and 1%-1.8% respectively since 2018 [5]. - For the first three quarters of 2024, Yingte Group reported a revenue of 247.77 billion yuan, a year-on-year increase of 3.59%, and a non-recurring net profit of 3.4 billion yuan, up 24.54% year-on-year [5].

公司于 2025 年 2 月 24 日召开十届九次董事会议，选举汪洋女士为公司董事长，任期 自本次董事会审议通过之日起至第十届董事会任期届满为止。 特此公告。 浙江英特集团股份有限公司董事会 2025 年 2 月 25 日 浙江英特集团股份有限公司 关于变更公司董事长的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 浙江英特集团股份有限公司（以下简称"公司"）董事会于 2025 年 2 月 24 日收到公司董 事长应徐颉先生提交的书面辞职报告。根据组织安排，应徐颉先生不再兼任公司董事、董 事长、董事会专门委员会相关职务。应徐颉先生辞去前述职务后，不再担任公司任何职务。 截至本公告日，应徐颉先生持有公司股份 168,000 股，并将严格按照《中华人民共和国证 券法》等法律法规、部门规章的有关规定管理上述股票。应徐颉先生的辞职不会导致公 司董事会成员低于法定最低人数，不会影响公司董事会的正常运行。 应徐颉先生自 1995 年进入公司至今近三十年，在公司任职期间恪尽职守、勤勉尽责、 锐意进取，为公司规范运作、改革创新、转型发展等作出了重大贡献。对此，公司董事会 ...

| 证券代码：000411 | 证券简称：英特集团 | 公告编号：2025-009 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 2025 年 2 月 19 日，浙江英特集团股份有限公司以电子邮件、专人送达方式向全体董事 发出了召开十届九次（临时）董事会议的通知。会议于 2025 年 2 月 24 日采用通讯方式召 开。会议应到董事 10 人，实际出席会议的董事 10 人。本次会议的召开符合有关法律、行政 法规、部门规章、规范性文件和公司章程的规定。会议对通知中所列事项进行了表决，形成 以下决议： 一、审议通过了《关于选举公司董事长的议案》（同意 10 票、反对 0 票、弃权 0 票） 选举汪洋女士为董事长，任期至第十届董事会届满（简历见附件）。 浙江英特集团股份有限公司 十届九次董事会议决议公告 二、审议通过了《关于聘任公司副总经理的议案》（同意 10 票、反对 0 票、弃权 0 票） 聘任许可先生为副总经理，任期至第十届董事会届满（简历见附件）。 高级 ...

证券代码：000411 证券简称：英特集团 浙江英特集团股份有限公司投资者关系活动记录表 | | 康产业集团。 | | --- | --- | | | （三）公司零售板块发展如何？ | | | 回答：2024年上半年公司医药零售业务实现营业收入14.53亿元，现有英特怡 | | | 年、英特一洲、绍兴华虞、英特天华等多个医药零售子品牌，业务覆盖全省11地市， | | | 门店超200家，涵盖普通药店、DTP药店等。 | | | （四）公司医疗器械板块发展如何？ | | | 回答：2024年上半年公司医疗器械批发板块实现营业收入8.70亿元。目前该板 | | | 块主要由省医疗器械、英特科技和百善医疗三家子公司组成，各公司聚焦器械专业 | | | 细分领域。 | | | （五）公司应收账款回款周期减缓的原因？ | | | 回答：公司目前应收账款回款周期整体保持稳定，浙江省内不同区域及不同类 | | | 型客户应收账款回款周期存在差异。公司重视应收账款周转等相关指标的管理，已 | | | 建立覆盖业务全程的事前、事中和事后的信用风险管理体系，以此保障应收账款管 | | | 理的有效性。 | | 附件清单 | | ...

| 债券全称 | 浙江英特集团股份有限公司 | | | 2025 | 年度第一期超短期融资券 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 债券简称 | 英特集团 25 SCP001 | | | 债券代码 | | 012580355 | | | | 发行人名称 | 浙江英特集团股份 有限公司 | | | 发行总额（亿元） | | 3.0 | | | | 发行价格（元/百元 面值） | 100 | | | 面值（元） | | 100 | | | | 计息方式 | 附息固定 | | | 票面年利率 | | 1.91% | | | | 期限 | 267 | 日 | | 付息频率 | | 到期一次还本付息 | | | | 起息日 | 年 2025 2 13 | 月 | 日 | 到期（兑付）日 | 2025 | 年 11 | 月 7 | 日 | 2025年2月12日，公司完成了2025年度第一期超短期融资券的发行，有关情况如下： 通过"信用中国"网站查询，公司不是失信责任主体。 本期超短期融资券发行情况的有关文件详见上海清算所（www ...

浙江英特集团股份有限公司 十届八次董事会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 2025 年 1 月 13 日，浙江英特集团股份有限公司以电子邮件、专人送达方式向全体董事 发出了召开十届八次董事会议的通知。会议于 2025 年 1 月 20 日以通讯表决方式召开。会议 应到董事 11 人，实际出席会议的董事 11 人，缺席会议的董事 0 人。本次会议的召开符合有 关法律、行政法规、部门规章、规范性文件和公司章程的规定。会议采用记名表决方式对通 知中所列事项进行了表决，形成以下决议： 一、审议通过了《关于提请审议石塘医药产业园项目投资额的议案》（11 票同意，0 票反对，0 票弃权）。 | 证券代码：000411 | 证券简称：英特集团 | 公告编号：2025-005 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 具体内容披露在同日的巨潮资讯网（http://www.cninfo.com.cn）和证券时报上。 公司董事会战略委员会会议已审议通过了该议案。 特此公告。 浙江英特集团股份有 ...